Off-Label Promotion: 'Safe Harbor' Preferable To Expansive Free Speech Rulings
Executive Summary
Payer- and physician-directed communications would be best addressed through a regulatory 'safe harbor' rather than First Amendment challenges where the outcome might sweep up consumer-directed communications, lawyers say at FDA/CMS Summit.
You may also be interested in...
Keep Limits On Off-Label Promotion, Consumers And Patients Say
Prescribers can get information they need through continuing education programs and scientific conferences, non-industry stakeholders tell US FDA during second day of meeting on manufacturer communications for unapproved uses.
Off-Label Communications: Industry, FDA Debate Role Of Peer Review
Allowing manufacturers to share research on unapproved uses that has not been formally vetted and published raises transparency concerns, US FDA commissioner says; industry attorney counters that many useful data sources 'would never see the light of day' under current peer review approaches.
FDA's Off-Label Communication Changes Should Start With Payers – PhRMA
PhRMA Senior Counsel Jeffrey Francer offers three-step reform approach to loosening FDA’s restrictions, beginning with the 'low-hanging fruit' of talking with payers.